Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study evaluates the incidence of monoclonal B-cell lymphocytosis MBL) in patients with chronic hepatitis C and to determine if monoclonal b-cell lymphocytosis is affected by treatment for hepatitis C.
Full description
PRIMARY OBJECTIVES:
I. To determine the prevalence of MBL in patients with chronic hepatitis C who are to begin therapy with directly acting antiviral (DAA), and compare with clinic controls who are seen in the general medicine clinic at Mayo Clinic.
II. To determine the correlation between the specific subtype of MBL (CD5- MBL, atypical CLL-phenotype MBL and CLL-phenotype MBL) relative to the hepatitis C virus (HCV) genotype.
III. To assess the proportion of individuals with MBL who have an improvement in the circulating monoclonal B-cell population following therapy with DAA.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and have medical records reviewed throughout study.
Enrollment
Sex
Volunteers
Inclusion criteria
Individuals with chronic hepatitis C who are to begin therapy with DAA
Exclusion criteria
Individuals with chronic hepatitis C who have cirrhosis
29 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal